← Back to Clinical Trials
Recruiting NCT07398677

NCT07398677 SchoolCare: A Social Intervention Introducing Telepresence Robots and School Navigation to Reduce School Fragmentation for Children Undergoing Cancer Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07398677
Status Recruiting
Phase
Sponsor Rigshospitalet, Denmark
Condition School Attendance
Study Type INTERVENTIONAL
Enrollment 128 participants
Start Date 2026-02-20
Primary Completion 2028-09-30

Eligibility & Interventions

Sex All sexes
Min Age 5 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Telepresence robotSchool NavigatorTeleteaching and technical support

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 128 participants in total. It began in 2026-02-20 with a primary completion date of 2028-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Advances in pediatric cancer treatment have led to significant improvements in survival rates, where 5-year survival now exceeds 85%. Despite improved survival, children and adolescents who survive cancer often face significant short- and long-term psychosocial and physical late effects. Children undergoing cancer treatment often experience prolonged school absence, which disrupts their academic development and impedes critical socio-emotional growth during formative school years, with lasting consequences into adulthood. Together, these challenges underscore the need for targeted interventions that support educational continuity, promote school activity, and foster psychosocial well-being. The SchoolCare Intervention aims to reduce school absence experienced by children diagnosed with cancer during their treatment trajectory. The intervention introduces school navigation support in combination with the use of telepresence robots (TPRs) and a teleteaching program. TPRs enable the children to attend school remotely, when they are not able to attend physically. The study is designed to investigate the effectiveness of the intervention throughout a period of eight months for school-aged children (i.e., 5-17 years) who are diagnosed with cancer. The investigators hypothesize that telepresence robots will increase school attendance among children and adolescents diagnosed with cancer, representing our primary outcome (H1). Additionally, the investigators explore secondary outcomes by hypothesizing that the intervention will improve the social well-being of these children and adolescents (H2) and enhance their academic level (H3). By focusing on both school attendance and broader psychosocial and academic effects, this study will provide a comprehensive evaluation of the telepresence robot intervention and its potential to support educational continuity and well-being for children with cancer.

Eligibility Criteria

Children and adolescents are eligible for inclusion if they meet the following criteria: they are: (1) diagnosed with cancer or cancer-like diseases withing two months of inclusion (e.g., benign brain tumors, MDS, or LCH ); (2) have undergone a stem cell transplant, or have experienced cancer relapse or disease progression within the two months of inclusion; (3) aged 5-17 years; (4) admitted to the pediatric oncology ward at Copenhagen University Hospital, Aarhus University Hospital, or Aalborg University Hospital; (5) expected to experience disrupted schooling, defined as absence of more than one school day per week over an anticipated period of eight months; and (6) enrolled, or expected enrolment, in a school in Denmark during the eight month intervention period. Participants will be excluded if: (1) the children in intervention arm B obtain a telepresence robot outside of the SchoolCare intervention; (2) the child is unable to communicate in Danish; or (3) the child has physical or cognitive impairments that prevent them from operating or meaningfully engaging with the telepresence robot. Assessment of the latter criterion will be conducted jointly by hospital personnel and the school navigator to determine whether the child is likely to benefit from participation in the intervention. All reasons for exclusion will be documented and reported in accordance with CONSORT guidelines \[47\] supplemented by the CONSORT-SPI extended version of social and psychological interventions \[48\]. Parents and teachers of the participating children will also be included in the study and invited to complete questionnaires as well as take part in semi-structured interviews. Recruitment began on February 1st, 2026.

Contact & Investigator

Central Contact

Hanne B Larsen

✉ hanne.baekgaard.larsen@regionh.dk

📞 34459647

Frequently Asked Questions

Who can join the NCT07398677 clinical trial?

This trial is open to participants of all sexes, aged 5 Years or older, up to 17 Years, studying School Attendance. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07398677 currently recruiting?

Yes, NCT07398677 is actively recruiting participants. Contact the research team at hanne.baekgaard.larsen@regionh.dk for enrollment information.

Where is the NCT07398677 trial being conducted?

This trial is being conducted at Aalborg, Denmark, Aarhus, Denmark, Copenhagen, Denmark.

Who is sponsoring the NCT07398677 clinical trial?

NCT07398677 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 128 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology